ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
자궁내막 절제 기기 시장 규모는 2023년 35억 3,860만 달러에 달했습니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 4.95%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 47억 1,950만 달러에 달할 것으로 예상됩니다. 자궁내막 절제 기기에 대한 수요는 임신, 난소낭종, 자궁근종, 다낭성 난소 증후군, 자궁내막증과 같은 부인과 질환의 사례 증가, 기술 발전, 종합적인 생식 건강 모니터링에 대한 수요 증가 등의 요인으로 인해 2024년에서 2030년간 예측 기간 동안 자궁내막 절제 기기의 성장을 가속하는 주요 요인으로 작용하고 있습니다.
세계보건기구(WHO)의 2024년 자료에 따르면, 매년 중저소득 국가의 15-19세 청소년 사이에서 약 2,100만 건의 임신이 발생하며, 10-19세 청소년 산모는 20-24세 여성에 비해 자간전증, 산후 자궁내막염, 전신 감염과 같은 합병증에 걸릴 위험이 훨씬 더 높습니다. 자간전증, 산전 자궁내막염, 전신 감염 등의 합병증 위험이 현저히 높습니다.
또한, 전 세계적으로 매년 약 7,300만 건의 인공임신중절이 이루어지고 있습니다. 낙태는 의도하지 않은 임신의 61%, 전체 임신의 29%를 차지하며, 2023년 같은 자료에 따르면 다낭성 난소 증후군(PCOS)은 가임기 여성의 약 8-13%가 앓고 있는 것으로 나타났습니다. 이러한 유병률에도 불구하고 전 세계적으로 최대 70%의 환자가 진단되지 않은 채로 남아 있으며, PCOS는 무배란의 가장 빈번한 원인이며 불임의 주요 원인입니다. 또한, 자궁내막증은 전 세계 가임기 여성과 여아의 약 10%에 영향을 미치며, 약 1억 9,000만 명에 달하는 것으로 추산됩니다.
따라서 2024년부터 2030년까지 예측 기간 동안 위의 요인들이 종합적으로 전체 자궁내막 절제 기기 시장을 견인할 것으로 예상됩니다.
이 보고서는 세계 자궁내막 절제 기기 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별, 최종사용자별 동향, 경쟁 구도, 국가별 동향 등의 정보를 전해드립니다.
목차
제1장 자궁 내막 절제 기기 시장 보고서 서론
제2장 자궁 내막 절제 기기 시장 주요 요약
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 자궁 내막 절제 기기 시장의 주요 요인 분석
자궁 내막 절제 기기 시장 성장 촉진요인
자궁 내막 절제 기기 시장 기회
제6장 자궁 내막 절제 기기 시장 : Porter의 Five Forces 분석
제7장 자궁 내막 절제 기기 시장 평가
제품 유형별
최종사용자별
지역별
제8장 자궁 내막 절제 기기 시장 기업과 제품 개요
Medtronic
Johnson & Johnson Services, Inc.
Olympus Corporation
Minerva Surgical, Inc.
Hologic, Inc.
CooperSurgical Inc.
Richard Wolf GmbH
AngioDynamics
KARL STORZ SE & Co. KG
IDOMAN-MED
Arthrex, Inc.
Channel Medsystems, Inc.
Gynesonics
Boston Scientific Corporation
AEGEA Medical
제9장 KOL(Key Opinion Leader)의 견해
제10장 프로젝트 접근
제11장 DelveInsight에 대해
제12장 면책사항과 문의
LSH
영문 목차
영문목차
Endometrial Ablation Devices Market by Product Type (Cryoablation devices, Hydrothermal Ablators, Thermal Balloon Ablator, Radiofrequency Ablators, Microwave Ablators, and Others), End-User (Hospitals & Clinics, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the rising prevalence of gynecological disorders and increasing product developmental activities globally
The Endometrial Ablation Devices market was valued at USD 3,538.60 million in 2023, growing at a CAGR of 4.95% during the forecast period from 2024 to 2030 to reach USD 4,719.50 million by 2030. The demand for Endometrial Ablation Devices is witnessing positive growth owing to factors such as the increasing instances of gynecological disorders such as pregnancies, ovarian cysts, fibroids, polycystic ovary syndrome, endometriosis and others, advancements in technology, and the increasing demand for comprehensive reproductive health monitoring among others, that are acting as major factors driving the growth of the Endometrial Ablation Devices during the forecast period from 2024 to 2030.
Endometrial Ablation Devices Market Dynamics:
According to data from the World Health Organization 2024, each year, an estimated 21 million pregnancies occur among adolescents aged 15 to 19 years in low- and middle-income countries. Adolescent mothers, aged 10-19 years, face significantly higher risks of complications such as eclampsia, puerperal endometritis, and systemic infections compared to women aged 20-24 years.
Additionally, approximately 73 million induced abortions are performed globally each year. Induced abortions account for 61% of all unintended pregnancies and 29% of all pregnancies. The same source in 2023 stated that polycystic ovary syndrome (PCOS) affects approximately 8 to 13% of women of reproductive age. Despite its prevalence, up to 70% of those affected remain undiagnosed globally. PCOS stands as the most frequent cause of anovulation and is a major contributor to infertility. Also, endometriosis impacts approximately 10% of women and girls of reproductive age worldwide, affecting an estimated 190 million individuals.
As per the latest statistics given by the U.S. Department of Health & Human Services in February 2021, by the time women reach at the age of 50, between 20 to 80 percent of women are expected to have fibroids globally.
The high prevalence of reproductive health conditions such as adolescent pregnancy complications, polycystic ovary syndrome (PCOS), endometriosis, and uterine fibroids often lead to abnormal uterine bleeding, a primary indication for endometrial ablation. Increased awareness, earlier diagnoses, and the need for minimally invasive, effective treatments further accelerate market growth.
Therefore, the factors stated above collectively will drive the overall Endometrial Ablation Devices market during the forecast period from 2024 to 2030.
However, the risks of associated with endometrial ablation procedures, including infection, tearing of uterine wall, and hemorrhage and others may limit their end-user base, thus acting as key constraints limiting the growth of the Endometrial Ablation Devices.
Endometrial Ablation Devices Market by Product Type (Cryoablation devices, Hydrothermal Ablators, Thermal Balloon Ablator, Radiofrequency Ablators, Microwave Ablators, and Others), End-User (Hospitals & Clinics, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the Endometrial Ablation Devices market, the radiofrequency ablators category is estimated to amass a significant revenue share in the Endometrial Ablation Devices market in 2023. The market for radiofrequency ablators devices within the endometrial ablation segment is experiencing growth due to several factors rooted in clinical efficacy, patient outcomes, and healthcare trends.
Radiofrequency ablators provide a minimally invasive alternative for the treatment of abnormal uterine bleeding (AUB), offering a high success rate and reduced recovery times compared to traditional surgical methods such as hysterectomy. Growing investments by leading medical device manufacturers to innovate and promote radiofrequency ablators devices, coupled with increasing healthcare expenditure in emerging markets, are fueling market expansion.
Also, the increasing technological advancement is likely to bode well for market growth during the forecast period. For instance, in September 2021, Gynesonics received approval from the US FDA for their next-generation Sonata System 2.2 radiofrequency ablation of fibroid tumors. This Sonata technology platform integrates a commercial intrauterine ultrasound system with an advanced radiofrequency ablation device to provide incision-free, uterus-preserving treatment.
Hence, owing to all the aforementioned factors, the market will experience an increased demand for radiofrequency ablators thus driving the category growth in the Endometrial Ablation Devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall Endometrial Ablation Devices market:
Among all the regions, North America is expected to account for the highest proportion of the Endometrial Ablation Devices Market in 2023, out of all regions. This growth can be attributed to the large patient population suffering from ovarian cancer, and endometriosis, increasing investments in device modalities, and regulatory approvals which are acting as key factors contributing to the growth of the Endometrial Ablation Devices market in the North America region during the forecast period from 2024 to 2030.
Data from the Global Cancer Observatory 2024, stated that in 2022, 0.0245 million were affected by ovarian cancer, and by 2045, 0.0315 million are projected to be diagnosed with ovarian cancer in the region.
According to the American Cancer Society 2023, around 19,710 new cases of ovarian cancer were diagnosed in 2023 in the US. According to data from the Journal of Obstetrics and Gynecology Canada (2020), in a survey conducted from 2018-2019, the estimated prevalence of endometriosis was found to be 7%, out of which 84.1% of the women were aged between 18 and 29.
Endometrial Ablation Devices play a crucial role in the management of ovarian cancer and endometriosis. For ovarian cancer, these systems are essential for ablating tumors and guiding treatment decisions.
Increasing strategic planning among the key players will also drive the market of endometrial ablation devices. For instance, in February 2021, CooperSurgical announced the acquisition of AEGEA Medical and its FDA-approved Mara Water Vapor Ablation system. The acquisition complemented CooperSurgical's growing portfolio of medical products that were focused on clinic and practice-based women's health. Mara is an in-office treatment that ablated the lining of the uterus in under two minutes for treatment of Heavy Menstrual Bleeding (HMB) in women.
Also, in October 2021, Hologic, announced acquisition of Bolder Surgical, for USD 160 million. The complementary acquisition of Bolder Surgical added to Hologic's surgical product line, which included the NovaSure(R) endometrial ablation system for the treatment of abnormal uterine bleeding, the MyoSure(R) tissue removal devices for the treatment of intrauterine fibroids and polyps, the Acessa(R) laparoscopic radiofrequency ablation system for the treatment of fibroids, among others.
Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the Endometrial Ablation Devices market.
Endometrial Ablation Devices Market key players:
Some of the key market players operating in the endometrial ablation devices market include Medtronic, Johnson & Johnson Services, Inc., Olympus Corporation, Minerva Surgical, Inc., Hologic, Inc., CooperSurgical Inc., Richard Wolf GmbH, AngioDynamics, KARL STORZ SE & Co. KG, IDOMAN-MED, Arthrex, Inc., Channel Medsystems, Inc., Gynesonics, Boston Scientific Corporation, AEGEA Medical, and others.
Recent Developmental Activities in the Endometrial Ablation Devices Market:
In February 2023, Hologic announced the approval of NovaSure V5 global endometrial ablation device (GEA) in Canada and Europe, which is a minimally invasive device that emits precisely measure radio-frequency energy to safely remove the endometrium, to treat Abnormal Uterine Bleeding (AUB).
In December 2022, RF Medical received US Food and Drug Administration (FDA) approval for its MYGEN M-3004 generator and MYOBLATE radiofrequency ablation system. MYGEN M-3004 enables a combination of monopolar and bipolar modes to deliver radiofrequency energy, while MYOBLATE electrodes are intended for coagulation and ablation of soft tissue to treat fibroids in a minimally invasive manner.
Key Takeaways from the Endometrial Ablation Devices Market Report Study
Market size analysis for current ENDOMETRIAL ABLATION DEVICES market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the Endometrial Ablation Devices market
Various opportunities available for the other competitors in the Endometrial Ablation Devices market space
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current Endometrial Ablation Devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Endometrial Ablation Devices market growth in the coming future?
Target audience who can be benefited from this Endometrial Ablation Devices Market Report Study
Endometrial Ablation Devices product providers
Research organizations and consulting companies
Endometrial Ablation Devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in Endometrial Ablation Devices
Various end-users who want to know more about the Endometrial Ablation Devices market and the latest developments in the Endometrial Ablation Devices market
Frequently Asked Questions for the Endometrial Ablation Devices Market:
1. What are Endometrial Ablation Devices?
The Endometrial Ablation Devices are surgical devices that are used to remove a thin layer of tissue (endometrium) that lines the uterus. The devices are used for the treatment of heavy menstrual bleeding, endometrial cancer, gynecological disorders, and others.
2. What is the market for Endometrial Ablation Devices?
The Endometrial Ablation Devices market was valued at USD 3,538.60 million in 2023, growing at a CAGR of 4.95% during the forecast period from 2024 to 2030 to reach USD 4,719.50 million by 2030.
3. What are the drivers for the Endometrial Ablation Devices market?
The demand for Endometrial Ablation Devices is witnessing positive growth owing to factors such as the increasing instances of gynecological disorders such as pregnancies, ovarian cysts, fibroids, polycystic ovary syndrome, endometriosis and others, advancements in technology, and the increasing demand for comprehensive reproductive health monitoring among others, that are acting as major factors driving the growth of the Endometrial Ablation Devices during the forecast period from 2024 to 2030.
4. Who are the key players operating in the Endometrial Ablation Devices market?
Some of the key market players operating in the Endometrial Ablation Devices market include Medtronic, Johnson & Johnson Services, Inc., Olympus Corporation, Minerva Surgical, Inc., Hologic, Inc., CooperSurgical Inc., Richard Wolf GmbH, AngioDynamics, KARL STORZ SE & Co. KG, IDOMAN-MED, Arthrex, Inc., Channel Medsystems, Inc., Gynesonics, Boston Scientific Corporation, AEGEA Medical, and others.
5. Which region has the highest share in the Endometrial Ablation Devices market?
North America is expected to dominate the overall Endometrial Ablation Devices market during the forecast period from 2024 to 2030. This growth can be attributed to the large patient population suffering from ovarian cancer, and endometriosis, increasing investments in device modalities, and regulatory approvals which are acting as key factors contributing to the growth of the Endometrial Ablation Devices market in the North America region during the forecast period from 2024 to 2030.
